What's breaking now, across thousands of outlets.
(RTTNews) - Wednesday, Silexion Therapeutics (SLXN) said the first patient has been dosed in its global Phase 2/3 trial evaluating SIL204 in patients with locally advanced pancreatic cancer (LAPC).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Completed three-year PROTECT randomized controlled trial finds NaturalVue Multifocal 1 Day contact lens slowed myopia progression by 1.06 diopters and eye elongation by 0.58 mm at 36 months.1,2…
(RTTNews) - Wednesday, Ernexa Therapeutics (ERNA) reported positive results from three IND-enabling safety studies of ERNA-101, its investigational iMSC therapy for advanced cancers.
Patients at Jinnah Postgraduate Medical Center in Karachi can receive robot-assisted surgery, including complex cancer operations, free of charge.
You may not know her name, but South African lawyer and bioethicist Kwanele Asante has spent two decades pushing health institutions — from Soweto to the United Nations – to listen to the people their…
Please see full Prescribing Information, including Patient Information: https://www.azpicentral.com/pi.html?product=baxfendy ; Nearly half of all U.S.
A new study from the University of Missouri offers hope for those who are at significantly higher risk of developing Alzheimer's disease later in life.
